Cambridge Healthtech Institute’s 5th Annual

Adoptive T Cell Therapy 2: Development

Case Studies and Clinical Progress of CAR, NK, TCR, and TIL

August 30-31, 2018

In 2017, two CAR T cell therapies were approved by the Food and Drug Administration (FDA). With multiple engineered receptors making preclinical impact, many biotech and pharma companies are already entering other clinical trials in a race to get to market. Has this promising field finally reached a tipping point? Technical considerations and translational challenges relating to cell therapy development, manufacturing practicability, clinical trial approaches, cell quality and persistence, and patient management remain. Cambridge Healthtech Institute’s 5th Annual Adoptive T Cell Therapy 2: Development conference focuses on the steps needed to deliver CAR, TCR, NK, and TIL therapies to the clinic. Overall, this event addresses clinical progress, case studies, and the critical components for making adoptive T cell therapy work.


Preliminary Agenda

HEMATOLOGIC CANCERS

FEATURED PRESENTATION: A Translational Perspective of Development of Yescarta (Axicabtagene Ciloleucel), a First-in-Class CAR T Cell Product for Diffuse Large B Cell Lymphoma

Adrian Bot, MD, PhD, Vice President, Translational Sciences, Kite, a Gilead Company 

Facing the Challenges of Apheresis Network Management

Amy Hines, BSN, RN, Director, Collection Network Management, Be The Match BioTherapies

SOLID TUMORS

FEATURED PRESENTATION: Stress-Resistant T Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, FACS, FCCP, Associate Attending and Deputy Chief, Thoracic Surgery; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center; Director, Mesothelioma Program, Memorial Sloan Kettering Cancer Center

GOLD: Activation-Induced Payload Delivery for T Cell Therapies

Gus Zeiner, PhD, CSO, Chimera Bioengineering

Can Local Delivery Solve Efficacy and Safety Challenges in Solid Tumor Immuno-Oncology?

Janet R. Rea, MSPH, RAC, Senior Vice President, Regulatory Affairs, Quality and Clinical Affairs, Atossa Genetics

Developing Tumor Infiltrating Lymphocytes for the Treatment of Cancer

Maria Fardis, PhD, President & CEO, Iovance Biotherapeutics

Eutilex’s 4-1BB CTL Adoptive T Cell Therapy: Clinically Safe and First Efficacy in Solid Tumors

Agustin de la Calle, PhD, CBO, Eutilex Co., Ltd.


NEXT-GENERATION APPROACHES

PM21-NK Cells for Cancer Therapy

Robert Igarashi, PhD, President, CytoSen Therapeutics

A TCR-Based Chimeric Antigen Receptor

Even Walseng, PhD, Staff Scientist, Experimental Immunology Branch, National Cancer Institute, National Institutes of Health; Department of Immunology, Hospital Radiumhospitalet, Institute for Cancer Research, University of Oslo




For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497
Email: mabrown@healthtech.com


For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

#IOSummit